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ABSTRACT
Adult bladder tumor is estimated to be the 10th most common tumor worldwide. However, its incidence is much less common
in children. It is a disease of the elderly that peaks in the sixth decade of life. Nevertheless, bladder tumors could also affect
children, adolescents, and young adults with a prevalence of <1% in the first four decades of life. Ethiopathogenically and
epidemiologically, the frequent association with congenital malformations can also explain the occurrence of bladder tumors
by the cytotoxic action of chemotherapy treatment in the context of hematological malignancies in children. Most bladder
neoplasms are surgically resected. Cystoscopy, if possible with biopsy, confirms the diagnosis of anatomy pathology.
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INTRODUCTION
Bladder cancer (BC) is the most common malignancy of
the urinary tract. Bladder cancer is the 10th most common
form of cancer in the world, with about 549,000 new cases
and it is more common in men than in women, with
respective incidence and mortality rates of 9.6 and 3.2 per
100,000 in men: about 4 times those of women worldwide
[1,2].
It is a disease of the elderly that peaks in the sixth decade
of life. Nevertheless, bladder tumor could also affect
children, adolescents and young adults with a prevalence
of <1% in the first 4 decades of life [3,4]. Unlike adults,
few predisposing factors are identified in children [5].
MATERIALS AND METHODS
A Moroccan male aged 27 years old with a history of acute
myeloid leukemia which was treated and cured by
chemotherapy at the age of 9. His bladder tumor was
discovered at the age of 13 by hematuria, confirmed by a
trans-urethral resection of the bladder. Pathology result
spoke of papillary urothelial neoplasia. Admitted in 2018
for total clotting hematuria and the rest of the examination
was unremarkable. In front of this symptomatology, we
asked for an ultrasound completed by a uroscanner and a
cystoscopy.
Ultrasound: Vascularized endoluminal budding process
located at the base of the bladder lateralized to the left
measuring 40x20x17 mm
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Uroscanner: Bladder lesion process, at the level of the
postero-lateral wall on the left measuring 50x30 mm
without any impact on the upper urinary tract, nor local or
distant infiltration (Figure 1).

Figure 1: Bladder lesion process, at the level of the
postero-lateral wall on the left of 50x30 mm.
During surgery:
- Exploration: urethra and neck not invaded,
Bladder: right meatus seen, left meatus seen
2 processes at the level of the left lateral wall and the
fundus measuring respectively 20 and 10 mm (Figure 2).
- Procedure: complete and deep RTUTV.
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Figure 2: Cystoscopic image of a urothelial-like process
of the left lateral wall.
Postoperative follow-up is simple. Bladder catheterization
and irrigation: urine clearing is obtained at the third day.
Anatopathology result found papillary urothelial neoplasia
of low malignancy potential.
Patient received 18 sessions of BCG therapy. Cystoscopy
of control post BCG protocol (18 sessions): no tumor
recurrence.
DISCUSSION
The frequency of occurrence of second tumors can be
globally estimated at less than 5% of treated patients.
However, it is influenced by the nature of the primary
tumor, age, the cumulative dose of drugs received, and the
association with radiotherapy [10].
Cytotoxic agents implicated in the development of a
second tumor are those whose mechanism of action
involves an interaction with DNA, mainly alkylating
agents
(melphalan,
cyclophosphamide),
and
topoisomerase II inhibitors (etoposide, anthracyclines)
[10].
A history of chemotherapy is associated with a fourfold
increased risk of bladder tumor, especially in cases of
familial retinoblastoma, cyclophosphamide exposure, or
pelvic irradiation . In a pediatric series of 12 cases, Di
Carlo found two cases of tumor history: an immature
ovarian teratoma surgically treated two years before and a
rhabdoid tumor irradiated 8 years before [11].
The most frequent urinary signs are: frequent and recurrent
urinary infections, total clotting hematuria and acute or
subacute retention of urine which would almost always be
the first clinical sign rarely is the discovery of a suprapubic
mass corresponding to a vesical globe [12].
The clinical examination is usually normal, rarely it is the
discovery of a suprapubic mass corresponding to a bladder
globe or to the tumor itself.
This is the first-line examination because of its safety and
ease of performance. Ultrasound can, if performed under
good conditions, show a thickening of the bladder wall or
an intra-vesical process.
Imaging can also show intra-vesical extension, mainly in
the form of intra-vesical buds. It is important to note the
invasion of different parts of the bladder, trigone, lateral
faces, dome, ureters. The appearance may be in the form
of true intravesical buds or vegetations but also a simple
thickening of the walls [13,14]. Other radiological
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examinations, in particular CT or MRI, are never
performed in the first instance, but only as part of the
assessment of an invasive tumor and also to look for
possible invasion of deep lymph nodes, especially lumbar
and pelvic lymph nodes and liver metastases [15].
The diagnosis of certainty can only be obtained by
histopathological examination of a tissue sample. In
addition to the clinical and radiological evidence, the
essential step in the diagnosis is the biopsy, which is
essential before treatment can be considered.
It is an endoscopic examination that allows to: visualize
the tumor(s) and specify the number, the location and the
aspect of the lesions.
TURT is a first line of treatment for all possible bladder
cancers. This surgery may be the only treatment needed
for bladder cancer that is limited to the superficial layer of
the bladder. In our case the recurrence occurred 10 years
after the resection despite it was a low risk bladder tumor.
The treatment includes in all cases endoscopic resection of
the tumor for anatomopathological examination. This
treatment is usually sufficient. In exceptional cases of
high-grade tumor, partial cystectomy of the tumor area is
indicated, as well as complementary treatments:
intravesical instillations of BCG, Mitomycin, or MVAC
(methotrexate, vinblastine, adriamycin, cisplatin), based
on adult protocols. There are currently no
recommendations for monitoring in children. Therefore,
they are monitored according to the "adult" protocol [1618].
Fortunately, bladder tumors are often considered
superficial and low grade (I - II) with low malignant
potential in children and adolescents, which was found in
our patient. In the general population, characteristics
associated with a higher risk of bladder cancer include
male gender, being a current or former regular cigarette
smoker, exposure to aromatic amines, treatment with
drugs such as cyclophosphamide, and exposure to
radiation from the pelvis [17,18].
The prognosis is highly dependent on the initial histology.
In this age group, urothelial tumors are most often noninvasive, with an excellent prognosis. Recurrences are rare
before the age of 20 years. Nevertheless, survival was
100% after 4.5 years of follow-up, without progressive
disease. This frequency increases in parallel with the
increase in the frequency of high-grade and high-stage
stages. Invasive tumors are very rare in children, but are
possible and their prognosis is close to that of adults. We
can cite the cases of Neogi [17] (high grade carcinoma
infiltrating the muscle in a 4 year old child, which evolved
favorably after partial cystectomy. The overall prognosis
is excellent with a very low mortality: 0% in the review by
Di Carlo [11].
CONCLUSION
Bladder tumors in children are rare, its diagnosis should be
suspected in children with obstructive lower urinary tract
syndrome associated or not with hematuria and/or
infection with imaging data, and cystoscopy if possible
with biopsy confirms the diagnosis on pathology. Younger
patients with epithelial neoplasms tend to have low stage,
low grade tumors and a lower recurrence rate and most
neoplasms have been surgically resected.
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